Sustiva

Country: European Union

Language: Dutch

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

efavirenz

Available from:

Bristol-Myers Squibb Pharma EEIG

ATC code:

J05AG03

INN (International Name):

efavirenz

Therapeutic group:

Antivirale middelen voor systemisch gebruik

Therapeutic area:

HIV-infecties

Therapeutic indications:

Sustiva is geïndiceerd voor de behandeling van antivirale combinatietherapie met volwassenen die jonger zijn met humaan-immunodeficiëntievirus-1 (HIV-1), adolescenten en kinderen van drie jaar en ouder.. Sustiva is niet voldoende bestudeerd bij patiënten met gevorderde HIV-ziekte, namelijk bij patiënten met CD4-tellingen < 50 cellen/mm3, of na falen van protease-remmer (PI)-bevattende regimes. Hoewel cross-weerstand van efavirenz met PIs niet is gedocumenteerd, er zijn op dit moment onvoldoende gegevens over de effectiviteit van het latere gebruik van de PI-gebaseerde combinatietherapie na de mislukking van de regimes met Sustiva.

Product summary:

Revision: 48

Authorization status:

Erkende

Authorization date:

1999-05-28

Patient Information leaflet

                                1/1
EU-NUMMER
FANTASIENAAM
STERKTE
FARMACEUTISCHE
VORM
TOEDIENINGSWEG
VERPAKKING
VERPAKKINGS-GROOTTE
EU/1/99/110/001
Sustiva
50 mg
Capsule, hard
Oraal
fles (HDPE)
30 capsules
EU/1/99/110/002
Sustiva
100 mg
Capsule, hard
Oraal
fles (HDPE)
30 capsules
EU/1/99/110/003
Sustiva
200 mg
Capsule, hard
Oraal
fles (HDPE)
90 capsules
EU/1/99/110/004
Sustiva
200 mg
Capsule, hard
Oraal
blisterverpakking (alu/PVC)
42 capsules
EU/1/99/110/008
Sustiva
600 mg
Filmomhulde tablet
Oraal
fles (HDPE)
30 tabletten
EU/1/99/110/009
Sustiva
600 mg
Filmomhulde tablet
Oraal
blisterverpakking (alu)
30 tabletten
EU/1/99/110/010
Sustiva
600 mg
Filmomhulde tablet
Oraal
blisterverpakking (alu)
90 tabletten
Geneesmiddel niet langer geregistreerd
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1/1
EU-NUMMER
FANTASIENAAM
STERKTE
FARMACEUTISCHE
VORM
TOEDIENINGSWEG
VERPAKKING
VERPAKKINGS-GROOTTE
EU/1/99/110/001
Sustiva
50 mg
Capsule, hard
Oraal
fles (HDPE)
30 capsules
EU/1/99/110/002
Sustiva
100 mg
Capsule, hard
Oraal
fles (HDPE)
30 capsules
EU/1/99/110/003
Sustiva
200 mg
Capsule, hard
Oraal
fles (HDPE)
90 capsules
EU/1/99/110/004
Sustiva
200 mg
Capsule, hard
Oraal
blisterverpakking (alu/PVC)
42 capsules
EU/1/99/110/008
Sustiva
600 mg
Filmomhulde tablet
Oraal
fles (HDPE)
30 tabletten
EU/1/99/110/009
Sustiva
600 mg
Filmomhulde tablet
Oraal
blisterverpakking (alu)
30 tabletten
EU/1/99/110/010
Sustiva
600 mg
Filmomhulde tablet
Oraal
blisterverpakking (alu)
90 tabletten
Geneesmiddel niet langer geregistreerd
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 14-03-2024
Summary of Product characteristics Summary of Product characteristics Bulgarian 14-03-2024
Public Assessment Report Public Assessment Report Bulgarian 26-01-2018
Patient Information leaflet Patient Information leaflet Spanish 14-03-2024
Public Assessment Report Public Assessment Report Spanish 26-01-2018
Patient Information leaflet Patient Information leaflet Czech 14-03-2024
Public Assessment Report Public Assessment Report Czech 26-01-2018
Patient Information leaflet Patient Information leaflet Danish 14-03-2024
Public Assessment Report Public Assessment Report Danish 26-01-2018
Patient Information leaflet Patient Information leaflet German 14-03-2024
Public Assessment Report Public Assessment Report German 26-01-2018
Patient Information leaflet Patient Information leaflet Estonian 14-03-2024
Public Assessment Report Public Assessment Report Estonian 26-01-2018
Patient Information leaflet Patient Information leaflet Greek 14-03-2024
Public Assessment Report Public Assessment Report Greek 26-01-2018
Patient Information leaflet Patient Information leaflet English 14-03-2024
Public Assessment Report Public Assessment Report English 26-01-2018
Patient Information leaflet Patient Information leaflet French 14-03-2024
Public Assessment Report Public Assessment Report French 26-01-2018
Patient Information leaflet Patient Information leaflet Italian 14-03-2024
Public Assessment Report Public Assessment Report Italian 26-01-2018
Patient Information leaflet Patient Information leaflet Latvian 14-03-2024
Public Assessment Report Public Assessment Report Latvian 26-01-2018
Patient Information leaflet Patient Information leaflet Lithuanian 14-03-2024
Summary of Product characteristics Summary of Product characteristics Lithuanian 14-03-2024
Public Assessment Report Public Assessment Report Lithuanian 26-01-2018
Patient Information leaflet Patient Information leaflet Hungarian 14-03-2024
Summary of Product characteristics Summary of Product characteristics Hungarian 14-03-2024
Public Assessment Report Public Assessment Report Hungarian 26-01-2018
Patient Information leaflet Patient Information leaflet Maltese 14-03-2024
Public Assessment Report Public Assessment Report Maltese 26-01-2018
Patient Information leaflet Patient Information leaflet Polish 14-03-2024
Public Assessment Report Public Assessment Report Polish 26-01-2018
Patient Information leaflet Patient Information leaflet Portuguese 14-03-2024
Summary of Product characteristics Summary of Product characteristics Portuguese 14-03-2024
Public Assessment Report Public Assessment Report Portuguese 26-01-2018
Patient Information leaflet Patient Information leaflet Romanian 14-03-2024
Public Assessment Report Public Assessment Report Romanian 26-01-2018
Patient Information leaflet Patient Information leaflet Slovak 14-03-2024
Public Assessment Report Public Assessment Report Slovak 26-01-2018
Patient Information leaflet Patient Information leaflet Slovenian 14-03-2024
Summary of Product characteristics Summary of Product characteristics Slovenian 14-03-2024
Public Assessment Report Public Assessment Report Slovenian 26-01-2018
Patient Information leaflet Patient Information leaflet Finnish 14-03-2024
Public Assessment Report Public Assessment Report Finnish 26-01-2018
Patient Information leaflet Patient Information leaflet Swedish 14-03-2024
Public Assessment Report Public Assessment Report Swedish 26-01-2018
Patient Information leaflet Patient Information leaflet Norwegian 14-03-2024
Summary of Product characteristics Summary of Product characteristics Norwegian 14-03-2024
Patient Information leaflet Patient Information leaflet Icelandic 14-03-2024
Summary of Product characteristics Summary of Product characteristics Icelandic 14-03-2024
Patient Information leaflet Patient Information leaflet Croatian 14-03-2024
Public Assessment Report Public Assessment Report Croatian 26-01-2018

Search alerts related to this product

View documents history